Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 2/2018

01-04-2018 | Original Article

Monitoring the estimated glomerular filtration rate (eGFR) in patients with small-cell lung cancer during chemotherapy: equations based on serum creatinine or cystatin C?

Authors: Xue Tian, Xinxing Zhang, Min Yu, You Lu, Zhenyu Ding, Meijuan Huang, Feng Peng, Li Ren, Jin Wang, Yongsheng Wang, Yong Xu, Jiang Zhu, Lin Zhou, Xiaojuan Zhou, Min Deng, Xin Tang, Youling Gong

Published in: International Journal of Clinical Oncology | Issue 2/2018

Login to get access

Abstract

Background

This study compared the differences between the estimated glomerular filtration rate (eGFR) calculated by several equations based on serum creatinine (Scr) and cystatin C (CysC) concentrations for monitoring renal function in patients with small-cell lung cancer (SCLC) during chemotherapy.

Methods

Seventy-one patients with SCLC were retrospectively analyzed. The eGFR before and after each chemotherapy cycle was calculated by the following equations: the chronic kidney disease epidemiology collaboration (CKD-EPI) equation, the modification of diet in renal disease (MDRD) equation, the Cockcroft–Gault (CG) equation, and five CysC-based equations. The patients were compared among the different eGFR groups.

Results

The mean decreases in eGFRCKD-EPI (−2.25 ± 9.89 ml/min/1.73 m2) between each treatment cycle were more significant than the decreases in eGFRCG (−0.46 ± 10.17 ml/min/1.73 m2), eGFRMDRD (−0.48 ± 9.79 ml/min/1.73 m2), and five calculated eGFRCysC (p < 0.05). Single-/multiparameter analyses showed that patients with a higher body mass index (BMI >23) and receiving more treatment cycles (>3) were at increased risk for developing renal impairment with an eGFR less than 60 ml/min/1.73 m2 during chemotherapy.

Conclusions

The eGFR calculated by the CKD-EPI equation changed more significantly between each chemotherapy cycle than did the eGFR from the other equations based on Scr or CysC in patients with SCLC. Oncologists should pay more attention to the renal function of specific patient groups during treatment.
Literature
1.
2.
3.
da Silva J, Mesler D (2001) Acute renal failure as a result of malignancy. In: Molitoris B, Finn W (eds) Acute renal failure: a companion to Brenner and Rector’s The Kidney. Harcourt, Indianapolis, pp 312–321
4.
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41CrossRefPubMed
5.
Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461–470CrossRefPubMed
6.
7.
Michels WM, Grootendorst DC, Verduijn M et al (2010) Performance of the Cockcroft–Gault, MDRD, and new CKD-EPI equations in relation to GFR, age, and body size. Clin J Am Soc Nephrol 5:1003–1009CrossRefPubMedPubMedCentral
8.
9.
Chew JSC, Saleem M, Florkowski CM et al (2008) Cystatin C: a paradigm of evidence-based laboratory medicine. Clin Biochem Rev 29:47–62PubMedPubMedCentral
10.
Stabuc B, Vrhovec L, Stabuc-Silih M et al (2000) Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. Clin Chem 46:193–197PubMed
11.
Thomas F, Seronie-Vivien S, Gladieff L et al (2005) Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin. Clin Pharmacokinet 44:1305–1316CrossRefPubMed
12.
Benohr P, Grenz A, Hartmann JT et al (2006) Cystatin C: a marker for assessment of the glomerular filtration rate in patients with cisplatin chemotherapy. Kidney Blood Press Res 29:32–35CrossRefPubMed
13.
Satariano WA, Ragland DR (1994) The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104–110CrossRefPubMed
14.
15.
Tan GD, Lewis AV, James TJ et al (2002) Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes: reproducibility and accuracy compared with standard measures and iohexol clearance. Diabetes Care 25:2004–2009CrossRefPubMed
16.
Larsson A, Malm J, Grubb A et al (2004) Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest 64:25–30CrossRefPubMed
17.
Grubb A, Björk J, Lindström V et al (2005) A cystatin C-based equation without anthropometric variables estimates glomerular filtration rate better than creatinine clearance using the Cockcroft–Gault equation. Scand J Clin Lab Invest 65:153–162CrossRefPubMed
18.
Grubb A, Nyman U, Björk J et al (2005) Simple cystatin C-based prediction equations for glomerular filtration rate compared with the Modification of Diet in Renal Disease prediction equation for adults and the Schwartz and the Counahan–Barratt prediction equations for children. Clin Chem 51:1420–1431CrossRefPubMed
19.
Sjöström P, Tidman M, Jones I (2005) Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans. Scand J Clin Lab Invest 65:111–124CrossRefPubMed
20.
Levey AS, Coresh J, Greene T et al (2006) Chronic Kidney Disease Epidemiology Collaboration: using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247–254CrossRefPubMed
21.
Stevens LA, Coresh J, Feldman HI et al (2007) Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 18:2749–2757CrossRefPubMed
22.
Wong TY, Tai ES (2009) The CKD-EPI equation and MDRD study equation find similar prevalence of chronic kidney disease in Asian populations. Ann Intern Med 151:892–893CrossRefPubMed
23.
Lustgarten JA, Wenk RE (1972) Simple, rapid, kinetic method for serum creatinine measurement. Clin Chem 18:1419–1422PubMed
24.
Poggio ED, Wang XL, Greene T et al (2005) Performance of the modification of diet in renal disease and Cockcroft–Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 16:459–466CrossRefPubMed
25.
Mojiminiyi OA, Marouf R, Abdella N et al (2002) Serum concentration of cystatin C is not affected by cellular proliferation in patients with proliferative haematological disorders. Ann Clin Biochem 39:308–310CrossRefPubMed
26.
Bárdi E, Bobok I, Oláh AV et al (2004) Cystatin C is a suitable marker of glomerular function in children with cancer. Pediatr Nephrol 19:1145–1147CrossRefPubMed
27.
Sokol JP, Schiemann WP (2004) Cystatin C antagonizes transforming growth factor β signaling in normal and cancer cells. Mol Cancer Res 2:183–195PubMed
28.
29.
Tavera C, Leung-Tack J, Prevot D et al (1992) Cystatin C secretion by rat glomerular mesangial cells: autocrine loop for in vitro growth-promoting activity. Biochem Biophys Res Commun 182:1082–1088CrossRefPubMed
30.
Cox JL, Sexton PS, Green TJ et al (1999) Inhibition of B16 melanoma metastasis by overexpression of the cysteine proteinase inhibitor cystatin C. Melanoma Res 9:369–374CrossRefPubMed
31.
32.
Kos J, Stabuc B, Cimerman N et al (1998) Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem 44:2556–2557PubMed
33.
Naumnik W, Niklinska W, Ossolinska M et al (2009) Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy. Folia Histochem Cytobiol 47:207–213CrossRefPubMed
34.
Strojan P, Svetic B, Smid L et al (2004) Serum cystatin C in patients with head and neck carcinoma. Clin Chim Acta 344:155–161CrossRefPubMed
35.
Mussap M, Plebani M (2004) Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci 41:467–550CrossRefPubMed
36.
Poole SG, Dooley MJ, Rischin D (2002) A comparison of bedside renal function estimates and measured glomerular filtration rate (TC99m-DTPA clearance) in cancer patients. Ann Oncol 13:949–955CrossRefPubMed
37.
Metadata
Title
Monitoring the estimated glomerular filtration rate (eGFR) in patients with small-cell lung cancer during chemotherapy: equations based on serum creatinine or cystatin C?
Authors
Xue Tian
Xinxing Zhang
Min Yu
You Lu
Zhenyu Ding
Meijuan Huang
Feng Peng
Li Ren
Jin Wang
Yongsheng Wang
Yong Xu
Jiang Zhu
Lin Zhou
Xiaojuan Zhou
Min Deng
Xin Tang
Youling Gong
Publication date
01-04-2018
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 2/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-017-1206-y

Other articles of this Issue 2/2018

International Journal of Clinical Oncology 2/2018 Go to the issue

Original Article

A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy

Original Article

Impact of a robotic surgical system on treatment choice for men with clinically organ-confined prostate cancer

Original Article

First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake

Original Article

Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma

Original Article

Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial

Original Article

Esophageal squamous cell neoplasia is an independent negative prognostic factor for head and neck cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits